<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0910246027
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Bilvardi
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BIVALIRUDIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        10012.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hainan Poly Pharm. Co., Ltd." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hainan Poly Pharm. Co., Ltd.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)	
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AE06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Bilvardi contains a substance called bivalirudin which is an antithrombotic medicine. Antithrombotics are medicines which prevent the formation of blood clots (thrombosis).</p><p>Bilvardi is used to treat patients:</p><ul><li>With chest pain due to heart disease (acute coronary syndromes - ACS)</li><li>Who are having surgery to treat blockages in their blood vessels (angioplasty and/or percutaneous coronary intervention - PCI).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Bilvardi</strong></p><ul><li>If you are allergic to Bilvardi or any of the other ingredients of this medicine (listed in section 6) or hirudins (other blood thinning medicines).</li><li>If you have, or have recently had, any bleeding from your stomach, intestines, bladder or other organs, for example, if you have noticed abnormal blood in your stools or urine (except from menstrual bleeding).</li><li>If you have, or have had, difficulty with your blood clotting (a low platelet count).</li><li>If you have severe high blood pressure.</li><li>If you have an infection of the heart tissue.</li><li>If you have severe kidney problems or if you need kidney dialysis.</li></ul><p>Check with the doctor if you are unsure.</p><p><strong>Warnings and precautions</strong></p><p><em>Talk to your doctor before using </em><em>Bilvardi</em><em>.</em></p><ul><li>If bleeding occurs (if this happens, treatment with Bilvardi will be stopped). Throughout your treatment, the doctor will check you for any signs of bleeding.</li><li>If you have been treated before with medicines similar to Bilvardi (e.g. lepirudin).</li><li>Before the start of the injection or infusion, the doctor will tell you about the signs of allergic reaction. Such a reaction is uncommon (may affect up to 1 in 100 people).</li><li>If you are having radiation treatment in the vessels that supply blood to the heart (treatment called beta or gamma brachytherapy).</li></ul><p>After being treated with Bilvardi for a cardiac event, you should stay in the hospital for at least 24 hours and you should be monitored for any symptoms or signs similar to the ones that remind you of your cardiac event and resulted in your hospitalisation.</p><p><strong>Children and adolescents</strong></p><ul><li>If you are a child (less than 18 years of age), this medicine is not appropriate for you.<strong>&nbsp;</strong></li></ul><p><strong>Other medicines and Bilvardi</strong></p><p><em>Tell your doctor or pharmacist</em></p><ul><li>If you are taking or have recently taken or might take any other medicines.</li><li>If you are taking blood thinners or medicines to prevent blood clots (anticoagulants or antithrombotics e.g. warfarin, dabigatran, apixaban, rivaroxaban, acetylsalicylic acid, clopidogrel, prasugrel, ticagrelor).</li></ul><p>These medicines may increase the risk of side effects such as bleeding when given at the same time as bivalirudin. Your warfarin blood test result (INR test) may be affected by bivalirudin.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>Bilvardi should not be used during pregnancy, unless clearly necessary. Your doctor will decide whether or not this treatment is appropriate for you. If you are breast-feeding, the doctor will decide whether Bilvardi should be used.</p><p><strong>Driving and using machines</strong></p><p>The effects of this medicine are known to be short-term. Bilvardi is only given when a patient is in hospital. It is, therefore, unlikely to affect your ability to drive or to use machines.</p><p><strong>Bilvardi contains sodium</strong></p><p>Bilvardi contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your treatment with Bilvardi will be supervised by a doctor. The doctor will decide how much Bilvardi you receive, and will prepare the medicine.</p><p>The dose given depends on your weight and on the kind of treatment you are being given.</p><p><strong>Dosage</strong></p><p><em>For patients with acute coronary syndromes (ACS) who are treated medically the recommended starting dose is:</em></p><ul><li>0.1 mg/kg body weight as an intravenous injection, followed by an infusion (drip) into vein of 0.25 mg/kg body weight per hour for up to 72 hours.</li></ul><p>If, after this, you then need percutaneous coronary intervention (PCI) treatment, the dosage will be increased to:</p><ul><li>0.5 mg/kg body weight for the intravenous injection, followed by an infusion into vein of 1.75 mg/kg body weight, per hour for the duration of the PCI.</li><li>When this treatment is finished, the infusion may go back to 0.25 mg/kg body weight per hour for an additional 4 to 12 hours.</li></ul><p>If you need to have a coronary artery bypass graft operation, treatment with bivalirudin will either be stopped one hour before the operation or an additional dose of 0.5 mg/kg body weight will be given by injection followed by an infusion of 1.75 mg/kg body weight per hour for the duration of surgery.</p><p><em>For patients starting with percutaneous coronary intervention (PCI) the recommended dose is:</em></p><ul><li>0.75 mg/kg body weight as an intravenous injection, followed immediately by an infusion (drip) into vein of 1.75 mg/kg body weight, per hour for at least the duration of the PCI. The intravenous infusion may continue at this dose for up to 4 hours after the PCI and for STEMI patients (those with a severe type of heart attack) it should continue at this dose for up to 4 hours. The infusion may be followed by an infusion at a lower dose of 0.25 mg/kg body weight for an additional 4 to 12 hours.</li></ul><p>If you have kidney problems, the dose of Bilvardi may need to be reduced.</p><p>In the elderly, if their kidney function is decreased, the dose may need to be reduced.</p><p>The doctor will decide for how long you should be treated.</p><p>Bilvardi is for injection, followed by infusion (drip), into a vein (never into a muscle). This is administered and supervised by a doctor experienced in caring for patients with heart disease.</p><p><strong>If you receive more Bilvardi than you should</strong></p><p>Your doctor will decide how to treat you, including stopping the drug and monitoring for signs of ill effects.</p><p>If you have any further questions on the use of this medicine, ask your doctor</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them</p><p><strong>If you get any of the following, potentially serious, side effects: </strong></p><ul><li>Whilst you are in hospital: tell the doctor or nurse immediately</li><li>After you have left the hospital: contact your doctor directly or go immediately to the Emergency Department of your nearest hospital</li></ul><p>The most common (may affect up to 1 in 10 people) serious side effect of treatment with bivalirudin is major bleeding which could occur anywhere inside the body (e.g. stomach, digestive system (including vomiting blood or passing blood with the stools), abdomen, lungs, groin, bladder, heart, eye, ear, nose or brain). This may, rarely, result in a stroke or be fatal. Swelling or pain in the groin or the arm, back pain, bruising, headache, coughing blood, pink or red urine, sweating, feeling faint or sick or dizzy due to low blood pressure may be signs of internal bleeding. Bleeding is more likely to occur when bivalirudin is used in combination with other anticoagulant or antithrombotic medicines (see section 2 &lsquo;Other medicines and Bilvardi&rsquo;).</p><ul><li>Bleeding and bruising at the puncture site (after PCI treatment) may be painful. Rarely this may require surgery to repair the blood vessel in the groin (fistula, pseudoaneurysm) (may affect up to 1 in 1,000 people). Uncommonly (may affect up to 1 in 100 people) the number of blood platelets may be low which can worsen any bleeding. Gum bleeding (uncommon, may affect up to 1 in 100 people) is usually not serious.</li><li>Allergic reactions, are uncommon (may affect up to 1 in 100 people) and usually not serious but can become severe under some circumstances, and in rare cases may be fatal due to low blood pressure (shock). They may begin with limited symptoms such as itching, redness of the skin, rash or small bumps on the skin. Occasionally, reactions can be more severe with throat itching, throat tightening, swelling of the eyes, face, tongue or lips, high pitched whistling during inhaling (stridor), difficulty breathing or exhaling (wheezes).</li><li>Thrombosis (blood clot) is an uncommon side effect (may affect up to 1 in 100 people) which may result in serious or fatal complications such as heart attack. Thrombosis includes coronary artery thrombosis (blood clot in the heart arteries or within a stent being felt as a heart attack which can also be fatal) and/or thrombosis in the catheter, both of which are rare (may affect up to 1 in 1,000 people).</li></ul><p><strong>If</strong> <strong>you get any of the following, (potentially less serious), side effects:</strong></p><ul><li>Whilst you are in hospital: tell the doctor or nurse</li><li>After you have left hospital: first seek advice from your doctor. If you cannot get access to your doctor go immediately to the Emergency Department of your nearest hospital</li></ul><p><strong>Very common side effects: may affect more than 1 in 10 people</strong></p><ul><li>Minor bleeding</li></ul><p><strong>Common side effects: may affect up to 1 in 10 people</strong></p><ul><li>Anaemia (a low blood cell count)</li><li>Haematoma (bruising)</li></ul><p><strong>Uncommon side effects: may affect up to 1 in 100 people</strong></p><ul><li>Nausea (feeling sick) and/or vomiting (being sick)</li></ul><p><strong>Rare side effects: may affect up to 1 in 1000 people</strong></p><ul><li>INR test (warfarin blood test result) increased (see Section 2, Other medicines and Bilvardi)</li><li>Angina or chest pain</li><li>Slow heartbeat</li><li>Rapid heartbeat</li><li>Shortness of breath</li><li>Reperfusion injury (no or slow reflow): impaired flow in the heart arteries after they have been reopened</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package.</p><p><em>Reconstituted solution: </em>Store in a refrigerator (2-8&deg;C) for 24 hours. Avoid freezing.</p><p><em>Diluted solution: </em>The diluted solution is stored at 25&deg;C for 24 hours. Avoid freezing.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. &nbsp;The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is bivalirudin trifluoroacetate.</p><p>Each vial of Bilvardi 250 mg Powder for Concentrate for Solution for Injection/Infusion contains bivalirudin trifluoroacetate equivalent to 250 mg bivalirudin.</p><p>The other ingredients are mannitol and sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Bilvardi 250 mg Powder for Concentrate for Solution for Injection/Infusion is a white to off-white lyophilised powder in 10 ml single-use type I clear glass vials closed with a bromobutyl rubber stoppers and sealed with an aluminum-plastic overseal.
After reconstitution, it is a clear and colourless solution.
Pack size: 10 Vials. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Batch releaser</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p><strong>Bulk manufacturer</strong></p><p>Hainan Poly Pharm. Co., Ltd.</p><p>Guilinyang Economic Development Area</p><p>Meilan District, Haikou, Hainan 571127</p><p>People&rsquo;s Republic of China</p><p><strong>Under license from</strong></p><p>Edge Pharma Limited</p><p>Milner House, 14 Manchester Square London W1U 3PP, United Kingdom<br /><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>United Arab of Emirates</li></ul><p>Pharmacovigilance &amp; Medical Device Section</p><p>P.O. Box: 1853</p><p>Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health &amp; Prevention</p><p>Dubai</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 01/2024; version number Un1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي بلڨاردي على مادة تسمى بيفاليرودين وهو دواء مانع للخُثار. موانع الخُثار هي أدوية تمنع تكوُّن الجلطات الدموية (الخُثار).</p><p dir="RTL">يُستخدم بلڨاردي لعلاج المرضى:</p><ul dir="rtl"><li>الذين يعانون من آلام في الصدر بسبب أمراض القلب (متلازمات تاجية حادة)</li><li>الذين يخضعون لعملية جراحية لعلاج انسداد الأوعية الدموية (رأب الوعاء و/أو التدخل التاجي عن طريق الجلد)</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم بلڨاردي</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لبلڨاردي أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6) أو الهيرودينات (أدوية أخرى لتخثر الدم).</li><li>إذا كنت تعاني أو عانيت مؤخراً من أي نزيف من المعدة، الأمعاء المثانة أو أعضاء أخرى، على سبيل المثال، إذا لاحظت وجود دم غير طبيعي في البراز أو البول (باستثناء نزيف الدورة الشهرية).</li><li>إذا كنت تعاني أو عانيت من مشكلة في تخثر الدم (انخفاض عدد الصفائح).</li><li>إذا كنت تعاني من ارتفاع شديد في ضغط الدم.</li><li>إذا كنت تعاني من التهاب في أنسجة القلب.</li><li>إذا كنت تعاني من مشكلات حادة في الكلى أو إذا كنت بحاجة إلى غسيل كلوي.</li></ul><p dir="RTL">تحقق مع الطبيب إذا لم تكن متأكداً.</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL"><em>تحدث مع طبيبك قبل استخدام بلڨاردي.</em></p><ul dir="rtl"><li>إذا حدث نزيف (يتم إيقاف العلاج ببلڨاردي في حالة حدوث ذلك). سيفحصك الطبيب بحثاً عن وجود أي علامات نزيف طوال فترة علاجك.</li><li>إذا كنت قد تلقيت علاجاً من قبل بأدوية مشابهة لبلڨاردي (مثل ليبيرودين).</li><li>سيُخبرك الطبيب عن علامات رد الفعل التحسسي قبل بدء الحقن أو التسريب. يعد مثل هذا التفاعل غير شائع (قد يؤثر فيما يصل إلى شخص من بين كل 100 شخص).</li><li>إذا كنت تخضع لعلاج إشعاعي في الأوعية الدموية التي تمد القلب بالدم (يُعرف العلاج باسم معالجة كثبية بأشعة بيتا أو غاما).</li><li>يجب أن تبقى في المستشفى لمدة 24 ساعة على الأقل بعد العلاج باستخدام بلڨاردي لعلاج نوبة قلبية ويجب أن يتم مراقبتك بحثاً عن أي أعراض أو علامات مماثلة لتلك التي أدت إلى النوبة القلبية وتسببت في دخولك المستشفى.</li></ul><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><ul dir="rtl"><li>إذا كنت طفلاً (أقل من 18 عاماً)، فلن يكون هذا الدواء مناسباً لك.</li></ul><p dir="RTL"><strong>الأدوية الأخرى وبلڨاردي</strong></p><p dir="RTL"><em>أخبر طبيبك أو الصيدلي</em></p><ul dir="rtl"><li>إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أية أدوية أخرى.</li><li>إذا كنت تتناول مرققات الدم أو أدوية لمنع الجلطات الدموية (مضادات أو موانع التخثر مثل وارفارين، دابيجاتران، أبيكسابان، ريفاروكسابان، حمض أسيتيل ساليسيليك، كلوبيدوجريل، براسوغريل، تيكاغريلور).</li></ul><p dir="RTL">قد تزيد هذه الأدوية من خطر حدوث آثار جانبية مثل النزيف عند تناولها في الوقت نفسه مع بيفاليرودين. قد تتأثر نتيجة اختبار الدم الخاصة بوارفارين (اختبار النسبة المعيارية الدولية) ببيفاليرودين.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">اطلبي النصيحة من طبيبك قبل تناول هذا الدواء إذا كنت حاملاً أو مرضعاً، تعتقدين بأنك حاملاً أو تخططين لذلك.</p><p dir="RTL">يجب عدم استخدام بلڨاردي أثناء الحمل إلا في حالة الضرورة الواضحة. سيقرر طبيبك ما إذا كان هذا العلاج مناسباً لكِ أم لا. إذا كنتِ ترضعين طبيعياً، فسيقرر الطبيب ما إذا كان ينبغي استخدام بلڨاردي.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">تُعرف تأثيرات هذا الدواء بأنها قصيرة المدى. يتم إعطاء بلڨاردي فقط عندما يكون المريض في المستشفى. لذلك، من غير المحتمل أن يؤثر ذلك على قدرتك على القيادة أو استخدام الآلات</p><p dir="RTL"><strong>يحتوي بلڨاردي على الصوديوم</strong></p><p dir="RTL">يحتوي بلڨاردي على الصوديوم. يحتوي هذا الدواء على أقل من 1 ملمول صوديوم (23 ملغم) لكل زجاجة، فيمكن اعتباره أنه &rsquo;خالٍ من الصوديوم&lsquo; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيشرف الطبيب على علاجك باستخدام بلڨاردي. سيقرر الطبيب مقدار الجرعة التي يجب أن تتلقاها من بلڨاردي، وسيقوم بتحضير الدواء.</p><p dir="RTL">تعتمد الجرعة المعطاة على وزنك ونوع العلاج الذي تتلقاه.</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL"><em>للمرضى الذين يعانون من متلازمات تاجية حادة ويتم علاجهم طبياً، فإن جرعة البداية الموصى بها هي:</em></p><ul dir="rtl"><li>0.1 ملغم/كغم من وزن الجسم كحقنة عن طريق الوريد، يليها تسريب (بالتنقيط) في الوريد بمقدار 0.25 ملغم/كغم من وزن الجسم لكل ساعة لمدة تصل إلى 72 ساعة.</li></ul><p dir="RTL">إذا احتجت بعد ذلك إلى علاج التدخل التاجي عن طريق الجلد، فسوف تتم زيادة الجرعة إلى:</p><ul dir="rtl"><li>0.5 ملغم/كغم من وزن الجسم للحقن عن طريق الوريد، يليه تسريب في الوريد بمقدار 1.75 ملغم/كغم من وزن الجسم لكل ساعة طوال مدة التدخل التاجي عن طريق الجلد.</li><li>عند الانتهاء من هذا العلاج، قد يقل مقدار التسريب ليصل إلى 0.25 ملغم/كغم من وزن الجسم لكل ساعة لمدة تتراوح بين 4 ساعات و12 ساعة إضافية.</li></ul><p dir="RTL">إذا كنت بحاجة إلى إجراء عملية طعم مجازة للشريان التاجي، فسيتم إيقاف العلاج باستخدام بيفاليرودين قبل ساعة واحدة من العملية أو سيتم إعطاء جرعة إضافية بمقدار 0.5 ملغم/كغم من وزن الجسم عن طريق الحقن يليها تسريب بمقدار 1.75 ملغم/كغم من وزن الجسم لكل ساعة طوال مدة العملية الجراحية.</p><p dir="RTL"><em>للمرضى الذين بدأوا بالتدخل التاجي عن طريق الجلد، فإن الجرعة الموصى بها هي:</em></p><ul dir="rtl"><li>0.75 ملغم/كغم من وزن الجسم كحقن عن طريق الوريد، يليه فوراً تسريب (بالتنقيط) في الوريد بمقدار 1.75 ملغم/كغم من وزن الجسم لكل ساعة على الأقل طوال مدة التدخل التاجي عن طريق الجلد. قد يستمر التسريب الوريدي بهذه الجرعة لمدة تصل إلى 4 ساعات بعد التدخل التاجي عن طريق الجلد ويجب الاستمرار بهذه الجرعة لمرضى احتشاء عضلة القلب الناجم عن ارتفاع مقطع ST (أولئك الذين يعانون من نوع حاد من النوبات القلبية) لمدة تصل إلى 4 ساعات. يمكن أن يُتبَع التسريب بتسريب جرعة أقل مقدارها 0.25 ملغم/كغم من وزن الجسم لمدة تتراوح بين 4 ساعات و12 ساعة إضافية.</li></ul><p dir="RTL">إذا كنت تعاني من مشكلات في الكلى، فقد يلزم تقليل جرعة بلڨاردي.</p><p dir="RTL">إذا انخفضت وظائف الكلى لدى كبار السن، فقد يلزم تقليل الجرعة.</p><p dir="RTL">سيحدد الطبيب مدة علاجك.</p><p dir="RTL">بلڨاردي مخصص للحقن، يليه التسريب (بالتنقيط) في الوريد (لا يُحقن أبداً في العضل). يتم إعطاؤه والإشراف عليه من قِبل طبيب متمرس في رعاية مرضى القلب.</p><p dir="RTL"><strong>إذا تم إعطاؤك بلڨاردي أكثر من اللازم</strong></p><p dir="RTL">سيقرر طبيبك طريقة علاجك، بما في ذلك إيقاف الدواء ومراقبة علامات الآثار الضارة.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، اسأل طبيبك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong>إذا عانيت من أي من الآثار الجانبية التالية، والتي يُحتَمَل أن تكون خطيرة: </strong></p><ul dir="rtl"><li>أثناء وجودك في المستشفى: أخبر الطبيب أو الممرض على الفور</li><li>بعد مغادرة المستشفى: تواصل مع طبيبك مباشرةً أو توجه فوراً إلى قسم الطوارئ في أقرب مستشفى</li></ul><p dir="RTL">الآثار الجانبية الخطيرة الأكثر شيوعاً للعلاج باستخدام بيفاليرودين (قد تؤثر فيما يصل إلى شخص واحد من بين كل 10 أشخاص) هي النزيف الشديد الذي يمكن أن يحدث في أي مكان داخل الجسم (مثل المعدة، الجهاز الهضمي (بما في ذلك تقيؤ الدم أو خروج الدم مع البراز)، البطن، الرئتين، منطقة ما بين الفخذين، المثانة، القلب، العين، الأذن، الأنف أو الدماغ). قد يؤدي ذلك إلى سكتة دماغية أو يكون مميتاً في حالات نادرة. قد يكون التورم أو الألم في منطقة ما بين الفخذين أو الذراع، ألم الظهر، ظهور كدمات، الصداع، السعال المصحوب بالدم، البول باللون الزهري أو الأحمر، التعرق، الشعور بالإغماء أو الغثيان أو الدوار بسبب انخفاض ضغط الدم من علامات النزيف الداخلي. من المرجح أن يحدث النزيف عندما يتم استخدام بيفاليرودين في توليفة مع مضادات أو موانع التخثر الأخرى (انظر القسم 2 &rsquo;الأدوية الأخرى وبلڨاردي&lsquo;).</p><ul dir="rtl"><li>&nbsp;قد يكون النزيف والكدمات في موضع الثقب (بعد علاج التدخل التاجي عن طريق الجلد) مؤلماً. نادراً ما يتطلب هذا جراحة لإصلاح الأوعية الدموية في منطقة ما بين الفخذين (الناسور، أم الدم الكاذبة) (قد تؤثر فيما يصل إلى شخص واحد من بين كل 1000 شخص). قد ينخفض عدد الصفائح الدموية، وهو من الآثار غير الشائعة، (قد يؤثر فيما يصل إلى شخص واحد من بين كل 100 شخص)، وهو ما قد يؤدي إلى تفاقم أي نزيف. عادةً ما يكون نزيف اللثة غير خطير (غير شائع، قد يؤثر فيما يصل إلى شخص واحد من بين كل 100 شخص) .</li><li>تعد ردود الفعل التحسسية غير شائعة (قد تؤثر فيما يصل إلى شخص واحد من بين كل 100 شخص) وعادةً لا تكون خطيرة ولكن قد تشتد في بعض الظروف، وفي حالات نادرة قد تكون مميتة بسبب انخفاض ضغط الدم (صدمة). قد تبدأ بأعراض محدودة مثل الحكة، احمرار الجلد، الطفح الجلدي أو ظهور نتوءات صغيرة على الجلد. يمكن أن تكون ردود الفعل أكثر حدة من حين لآخر مثل حكة في الحلق، تصلب الحلق، تورم العينين، الوجه، اللسان أو الشفتين، الصفير العالي أثناء الاستنشاق (صرير)، صعوبة في التنفس أو الزفير (الأزيز).</li><li>التخثر (الجلطة الدموية) هو أثراً جانبياً غير شائع (قد تؤثر فيما يصل إلى شخص واحد من بين كل 100 شخص)، والذي قد يؤدي إلى مضاعفات خطيرة أو مميتة مثل النوبات القلبية. يشتمل التخثر على تخثر الشريان التاجي (جلطة دموية في شرايين القلب أو داخل دعامة يُشعر بها على أنها نوبة قلبية قد تكون مميتة أيضاً) و/أو التخثر في القسطرة، وكلاهما نادر (قد يؤثران فيما يصل إلى شخص واحد من بين كل 1000 شخص).</li></ul><p dir="RTL"><strong>إذا</strong> <strong>أصبت بأي من الآثار الجانبية التالية (والتي يحتمل أن تكون خطيرة):</strong></p><ul dir="rtl"><li>أثناء وجودك في المستشفى: أخبر الطبيب أو الممرض</li><li>بعد مغادرة المستشفى: أولاً، اطلب النصيحة من طبيبك. إذا لم تتمكن من التواصل مع طبيبك، فعليك التوجه فوراً إلى قسم الطوارئ في أقرب مستشفى</li></ul><p dir="RTL"><strong>آثار جانبية شائعة جداً: قد تؤثر في أكثر من شخص واحد من بين كل 10 أشخاص</strong></p><ul dir="rtl"><li>نزيف طفيف</li></ul><p dir="RTL"><strong>آثار جانبية شائعة: قد تؤثر فيما يصل إلى شخص واحد من بين كل 10 أشخاص</strong></p><ul dir="rtl"><li>فقر الدم (انخفاض عدد خلايا الدم)</li><li>ورم دموي (كدمات)</li></ul><p dir="RTL"><strong>آثار جانبية غير شائعة: قد تؤثر فيما يصل إلى شخص واحد من بين كل 100 شخص</strong></p><ul dir="rtl"><li>الغثيان (الشعور بالغثيان) و/أو القيء (الإعياء)</li></ul><p dir="RTL"><strong>آثار جانبية نادرة: قد تؤثر فيما يصل إلى شخص واحد من بين كل 1000 شخص</strong></p><ul dir="rtl"><li>زيادة اختبار النسبة المعيارية الدولية (نتيجة اختبار الدم الخاصة بالوارفارين) (انظر القسم 2، الأدوية الأخرى وبلڨاردي)</li><li>الذبحة الصدرية أو ألم الصدر</li><li>بطء ضربات القلب</li><li>سرعة ضربات القلب</li><li>ضيق التنفس</li><li>الإصابات الناتجة عن إعادة التروية (انعدام أو بطء إعادة التدفق): ضعف التدفق في شرايين القلب بعد إعادة فتحه</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL"><em>المحلول المحضر</em><em>: </em>يحفظ داخل الثلاجة (2-8&deg; مئوية) لمدة 24 ساعة. تجنب تجميده.</p><p dir="RTL"><em>المحلول المخفف</em><em>: </em>يحفظ المحلول المخفف عند درجة حرارة 25&deg; مئوية لمدة 24 ساعة. تجنب تجميده.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد &quot;EXP&quot;.&nbsp; يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي أسيتات ثلاثي فلور البيفاليرودين.</p><p dir="RTL">تحتوي كل زجاجة من بلڨاردي 250 ملغم مسحوق لتشكيل المركز ثم التخفيف للحقن/للتسريب على أسيتات ثلاثي فلور البيفاليرودين تكافئ 250 ملغم بيفاليرودين.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي مانيتول وهيدروكسيد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">بلڨاردي 250 ملغم مسحوق لتشكيل المركز ثم التخفيف للحقن/للتسريب هو مسحوق مجفد أبيض مائل إلى الأبيض المصفر في زجاجات معدة للاستخدام لمرة واحدة بحجم 10 مللتر من النوع رقم وحد مغلقة بسدادات مطاطية من البروموبوتيل ومحكم إغلاقها بغطاء من الألومنيوم-البلاستيك.</p><p dir="RTL">بعد التحضير، يكون محلول صافٍ وعديم اللون.</p><p dir="RTL">حجم العبوة: 10 زجاجات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق </strong><strong>ومحرر التشغيلة</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة للمستحضر النهائي</strong></p><p dir="RTL">شركة هاينان بولي فارم. المحدودة</p><p dir="RTL">منطقة جالينيانج للإنماء الاقتصادي</p><p dir="RTL">مقاطعة ميالان، هايكو، هاينان 571127</p><p dir="RTL">جمهورية الصين الشعبية</p><p dir="RTL"><strong>بترخيص من</strong></p><p dir="RTL">إيدج فارما المحدودة</p><p dir="RTL">منزل ميلنر، 14 ميدان مانشيستر لندن W1U 3PP،</p><p dir="RTL">المملكة المتحدة</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; الإمارات العربية المتحدة</p><p dir="RTL">قسم اليقظة الدوائية والجهاز الطبي</p><p dir="RTL">صندوق بريد: 1853</p><p dir="RTL">هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p dir="RTL">إدارة الدواء</p><p dir="RTL">وزارة الصحة ووقاية المجتمع</p><p dir="RTL">دبي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى</p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 01/2024؛ رقم النسخة Un1.0.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bilvardi 250 mg Powder for Concentrate for Solution for Injection/Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial of Bilvardi 250 mg Powder for Concentrate for Solution for Injection/Infusion contains bivalirudin trifluoroacetate equivalent to 250 mg bivalirudin.

Excipient(s) with known effect: Sodium. 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for concentrate for solution for injection/infusion.

White to off-white lyophilised powder.

After reconstitution, it is a clear and colourless solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bilvardi is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI.</p><p>Bilvardi is also indicated for the treatment of adult patients with unstable angina/non-ST segment elevation myocardial infarction (UA/NSTEMI) planned for urgent or early intervention.</p><p>Bilvardi should be administered with acetylsalicylic acid and clopidogrel.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bilvardi should be administered by a physician experienced in either acute coronary care or in coronary intervention procedures.</p><p><strong>Posology</strong></p><p><em>Patients undergoing PCI, including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI</em></p><p>The recommended dose of bivalirudin for patients undergoing PCI is an intravenous bolus of 0.75 mg/kg body weight followed immediately by an intravenous infusion at a rate of 1.75 mg/kg body weight/hour for at least the duration of the procedure. The infusion of 1.75 mg/kg body weight/hour may be continued for up to 4 hours post-PCI and at a reduced dose of 0.25 mg/kg body weight/hour for an additional 4 &ndash; 12 hours as clinically necessary. In STEMI patients the infusion of 1.75 mg/kg body weight/hour should be continued for up to 4 hours post-PCI and continued at a reduced dose of 0.25 mg/kg body weight/hour for an additional 4 &ndash; 12 hours as</p><p>clinically necessary (see section 4.4).</p><p>Patients should be carefully monitored following primary PCI for signs and symptoms consistent with myocardial ischaemia.</p><p><em>Patients with unstable angina/non-ST segment elevated myocardial infarction (UA/NSTEMI)</em></p><p>The recommended starting dose of bivalirudin for medically managed patients with acute coronary syndrome (ACS) is an intravenous bolus of 0.1 mg/kg followed by an infusion of 0.25 mg/kg/h. Patients who are to be medically managed may continue the infusion of 0.25 mg/kg/h for up to 72 hours. If the medically managed patient proceeds to PCI, an additional bolus of 0.5 mg/kg of bivalirudin should be administered before the procedure and the infusion increased to 1.75 mg/kg/h for the duration of the procedure. Following PCI, the reduced infusion dose of 0.25 mg/kg/h may be resumed for 4 to 12 hours as clinically necessary.</p><p>For patients who proceed to coronary artery bypass graft (CABG) surgery off pump, the intravenous infusion of bivalirudin should be continued until the time of surgery. Just prior to surgery, a 0.5 mg/kg bolus dose should be administered followed by a 1.75 mg/kg/h intravenous infusion for the duration of the surgery.</p><p>For patients who proceed to CABG surgery on pump, the intravenous infusion of bivalirudin should be continued until 1 hour prior to surgery after which the infusion should be discontinued and the patient treated with unfractionated heparin (UFH).</p><p>To ensure appropriate administration of bivalirudin, the completely dissolved, reconstituted and diluted product should be thoroughly mixed prior to administration (see section 6.6). The bolus dose should be administered by a rapid intravenous push to ensure that the entire bolus reaches the patient before the start of the procedure.</p><p>Intravenous infusion lines should be primed with bivalirudin to ensure continuity of drug infusion after delivery of the bolus.</p><p>The infusion dose should be initiated immediately after the bolus dose is administered, ensuring delivery to the patient prior to the procedure, and continued uninterrupted for the duration of the procedure. The safety and efficacy of a bolus dose of bivalirudin without the subsequent infusion has not been evaluated and is not recommended even if a short PCI procedure is planned.</p><p>An increase in the activated clotting time (ACT) may be used as an indication that a patient has received bivalirudin.</p><p>ACT values 5 minutes after bivalirudin bolus average 365 +/- 100 seconds. If the 5-minute ACT is less than 225 seconds, a second bolus dose of 0.3 mg/kg should be administered.</p><p>Once the ACT value is greater than 225 seconds, no further monitoring is required provided the 1.75 mg/kg/h infusion dose is properly administered.</p><p>Where insufficient ACT increase is observed, the possibility of medication error should be considered, for example inadequate mixing of bivalirudin or intravenous equipment failures.</p><p>The arterial sheath can be removed 2 hours after discontinuation of the bivalirudin infusion without anticoagulation monitoring.</p><p><em>Use with other anticoagulant therapy</em></p><p>In STEMI patients undergoing primary PCI, standard pre-hospital adjunctive therapy should include clopidogrel and may include the early administration of UFH (See section 5.1).</p><p>Patients can be started on Bilvardi 30 minutes after discontinuation of unfractionated heparin given intravenously, or 8 hours after discontinuation of low molecular weight heparin given subcutaneously.</p><p>Bilvardi can be used in conjunction with a GP IIb/IIIa inhibitor. For further information regarding the use of bivalirudin with or without a GP IIb/IIIa inhibitor, please see section 5.1.</p><p><em>Renal insufficiency</em></p><p>Bivalirudin contraindicated in patients with severe renal insufficiency (GFR &lt; 30 ml/min) and also in dialysis-dependent patients (see section 4.3).</p><p>In patients with mild or moderate renal insufficiency, the ACS dose (0.1 mg/kg bolus/0.25 mg/kg/h infusion) should not be adjusted.</p><p>Patients with moderate renal impairment (GFR 30-59 ml/min) undergoing PCI (whether being treated with bivalirudin for ACS or not) should receive a lower infusion rate of 1.4 mg/kg/h. The bolus dose should not be changed from the posology described under ACS or PCI above.</p><p>Patients with renal impairment should be carefully monitored for clinical signs of bleeding during PCI, as clearance of bivalirudin is reduced in these patients (see section 5.2).</p><p>If the 5-minute ACT is less than 225 seconds, a second bolus dose of 0.3 mg/kg should be administered and the ACT re-checked 5 minutes after the administration of the second bolus dose.</p><p>Where insufficient ACT increase is observed, the possibility of medication error should be considered, for example inadequate mixing of Bilvardi or intravenous equipment failures.</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is needed. Pharmacokinetic studies indicate that hepatic metabolism of bivalirudin is limited, therefore the safety and efficacy of bivalirudin have not been specifically studied in patients with hepatic impairment.</p><p><em>Elderly population</em></p><p>Increased awareness due to high bleeding risk should be exercised in the elderly because of age-related decrease in renal function. Dose adjustments for this age group should be on the basis of renal function.</p><p><em>Paediatric population</em></p><p>There is currently no indication for the use of bivalirudin in children less than 18 years old and no recommendation on a posology can be made. Currently available data are described in sections 5.1 and 5.2.</p><p><strong>Method of administration</strong></p><p>Bilvardi is intended for intravenous use.</p><p>Bilvardi should be initially reconstituted to give a solution of 50 mg/ml bivalirudin. Reconstituted material should then be further diluted in a total volume of 50 ml to give a solution of 5 mg/ml bivalirudin.</p><p>Reconstituted and diluted product should be thoroughly mixed prior to administration.</p><p>The reconstituted/diluted solution will be a clear to slightly opalescent, colourless solution. For instructions on reconstitution and dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bivalirudin is contraindicated in patients with:
•	A known hypersensitivity to the active substance or to any of the excipients listed in section 6.1, or to hirudins
•	Active bleeding or increased risk of bleeding because of haemostasis disorders and/or irreversible coagulation disorders 
•	Severe uncontrolled hypertension
•	Subacute bacterial endocarditis
•	Severe renal impairment (GFR < 30 ml/min) and in dialysis-dependent patients
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bilvardi is not intended for intramuscular use. Do not administer intramuscularly.</p><p><strong>Haemorrhage</strong></p><p>Patients must be observed carefully for symptoms and signs of bleeding during treatment particularly if bivalirudin is combined with another anticoagulant (see section 4.5). Although most bleeding associated with bivalirudin occurs at the site of arterial puncture in patients undergoing PCI, haemorrhage can occur at any site during therapy. Unexplained decreases in haematocrit, haemoglobin or blood pressure may indicate haemorrhage. Treatment should be stopped if bleeding is observed or suspected.</p><p>There is no known antidote to bivalirudin but its effect wears off quickly (T&frac12; is 25 &plusmn; 12 minutes).</p><p>Prolonged post PCI infusions of bivalirudin at recommended doses have not been associated with an increased rate of bleeding (see section 4.2).</p><p><strong>Co-administration with platelet inhibitors or anti-coagulants</strong></p><p>Combined use of anti-coagulant medicinal products can be expected to increase the risk of bleeding (see section 4.5). When bivalirudin is combined with a platelet inhibitor or an anti-coagulant medicine, clinical and biological parameters of haemostasis should be regularly monitored.</p><p>In patients taking warfarin who are treated with bivalirudin, International Normalised Ratio (INR) monitoring should be considered to ensure that it returns to pre-treatment levels following discontinuation of bivalirudin treatment.</p><p><strong>Hypersensitivity</strong></p><p>Allergic type hypersensitivity reactions were reported uncommonly (&ge; 1/1,000 to &le; 1/100) in clinical trials. Necessary preparations should be made to deal with this. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, tightness of chest, wheezing, hypotension and anaphylaxis. In the case of shock, the current medical standards for shock treatment should be applied. Anaphylaxis, including anaphylactic shock with fatal outcome has been reported very rarely (&le; 1/10,000) in post-marketing experience (see section 4.8).</p><p>Treatment-emergent positive bivalirudin antibodies are rare and have not been associated with clinical evidence of allergic or anaphylactic reactions. Caution should be exercised in patients previously treated with lepirudin who had developed lepirudin antibodies.</p><p><strong>Acute stent thrombosis</strong></p><p>Acute stent thrombosis (&lt; 24 hours) has been observed in patients with STEMI undergoing primary PCI and has been managed by Target Vessel Revascularisation (TVR) (see sections 4.8 and 5.1). The majority of these cases were non-fatal. This increased risk of acute stent thrombosis was observed during the first 4 hours following the end of the procedure among patients who either discontinued the infusion of bivalirudin at the end of the procedure or received a continued infusion at the reduced dose of 0.25 mg/kg/h (see section 4.2). Patients should remain for at least 24 hours in a facility capable of managing ischaemic complications and should be carefully monitored following primary PCI for signs and symptoms consistent with</p><p>myocardial ischaemia.</p><p><strong>Brachytherapy</strong></p><p>Intra-procedural thrombus formation has been observed during gamma brachytherapy procedures with bivalirudin.</p><p>Bivalirudin should be used with caution during beta brachytherapy procedures.</p><p><strong>Bilvardi contains sodium</strong></p><p>Bilvardi contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have been conducted with platelet inhibitors, including acetylsalicylic acid, ticlopidine, clopidogrel, abciximab, eptifibatide, or tirofiban. The results do not suggest pharmacodynamic interactions with these medicinal products.</p><p>From the knowledge of their mechanism of action, combined use of anti-coagulant medicinal products (heparin, warfarin, thrombolytics or antiplatelet agents) can be expected to increase the risk of bleeding.</p><p>In any case, when bivalirudin is combined with a platelet inhibitor or an anticoagulant, clinical and biological parameters of haemostasis should be regularly monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There are no or limited data from the use of bivalirudin in pregnant women. Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, parturition or post- natal development (see section 5.3).</p><p>Bilvardi should not be used during pregnancy unless the clinical condition of the woman requires treatment with bivalirudin.</p><p><strong>Breastfeeding</strong></p><p>It is unknown whether bivalirudin is excreted in human milk. Bivalirudin should be administered with caution in breast-feeding mothers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bivalirudin has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Summary of the safety profile</em></strong></p><ul><li>&middot;The most frequent serious and fatal adverse reactions are major haemorrhage (access site and non access-site bleeding, including intracranial haemorrhage) and hypersensitivity, including anaphylactic shock. Coronary artery thrombosis and coronary stent thrombosis with myocardial infarction, and catheter thrombosis have each been reported rarely. Administration errors may lead to fatal thrombosis.</li><li>In patients receiving warfarin, INR is increased by administration of bivalirudin.</li></ul><p><strong><em>Tabulated list of adverse reactions</em></strong></p><p>Adverse reactions for bivalirudin from HORIZONS, ACUITY, REPLACE-2 trials and post-marketing experience are listed by system organ class in Table 1.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very Common (</strong>&ge; <strong>1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common (</strong>&ge; <strong>1/100 to &lt; 1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon (</strong>&ge; <strong>1/1,000 to &lt; 1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare (</strong>&ge; <strong>1/10,000 to &lt; 1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare (&lt;1/10,000)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haemoglobin decreased</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Anaemia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity, including anaphylactic reaction and shock, including reports with fatal outcome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Intracranial haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Intraocular haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ear haemorrhage</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cardiac tamponade,</p><p>Pericardial haemorrhage,</p><p>Myocardial infarction,</p><p>Coronary artery thrombosis,</p><p>Bradycardia,</p><p>Ventricular tachycardia,</p><p>Angina pectoris,</p><p>Chest pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Minor haemorrhage at any site</p></td><td style="vertical-align:top"><p>Major haemorrhage at any site including reports with fatal outcome</p></td><td style="vertical-align:top"><p>Haematoma,</p><p>Hypotension</p></td><td style="vertical-align:top"><p>Coronary stent thrombosis including reports with fatal outcome<sup>c</sup></p><p>Thrombosis including reports with fatal outcome,</p><p>Arteriovenous fistula,</p><p>Catheter thrombosis,</p><p>Vascular pseudoaneurysm</p></td><td style="vertical-align:top"><p>Compartment syndrome<sup> a, b</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Epistaxis,</p><p>Haemoptysis,</p><p>Pharyngeal haemorrhage</p></td><td style="vertical-align:top"><p>Pulmonary haemorrhage</p><p>Dyspnoea<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage (including haematemesis, melaena, oesophageal haemorrhage, anal haemorrhage),</p><p>Retroperitoneal haemorrhage,</p><p>Gingival haemorrhage,</p><p>Nausea</p></td><td style="vertical-align:top"><p>Peritoneal haemorrhage,</p><p>Retroperitoneal haematoma,</p><p>Vomiting</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ecchymosis</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash,</p><p>Urticaria</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Back pain,</p><p>Groin pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematuria</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Access site haemorrhage,</p><p>Vessel puncture site haematoma &gt; 5 cm,</p><p>Vessel puncture site haematoma &lt; 5 cm</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Injection site reactions (Injection site discomfort, Injection site pain,</p><p>Puncture site reaction)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>INR increased<sup>d</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Reperfusion injury (no or slow reflow),</p><p>Contusion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>a. ADRs identified in post-marketing experience</p><p>b. Compartment syndrome has been reported as a complication of forearm haematoma following administration of bivalirudin via the radial access route in post-marketing experience</p><p>c. Further detail regarding stent thrombosis is provided in section 4.8: The HORIZONS Trial (Patients with STEMI undergoing primary PCI). For instructions for monitoring acute stent thrombosis, see section 4.4.</p><p>d. Section 4.4 describes precautions for INR monitoring when bivalirudin is co-administered with warfarin.</p><p><strong><em>Description of selected adverse reactions</em></strong></p><p><strong>Haemorrhage</strong></p><p>In all clinical studies bleeding data were collected separately from adverse reactions and are summarised in Table 6 together with the bleeding definitions used for each study.</p><p><em>The HORIZONS Trial (Patients with STEMI undergoing primary PCI)</em></p><ul><li>Platelets, bleeding and clotting</li></ul><p>In the HORIZONS study both major and minor bleeding occurred commonly (&ge; 1/100 to &lt; 1/10). The incidence of major and minor bleeding was significantly less in patients treated with bivalirudin versus patients treated with heparin plus a GP IIb/IIIa inhibitor. The incidence of major bleeding is shown in Table 6. Major bleeding occurred most frequently at the sheath puncture site. The most frequent event was a haematoma &lt;5 cm at puncture site.</p><p>In the HORIZONS study, thrombocytopenia was reported in 26 (1.6%) of bivalirudin-treated patients and in 67 (3.9%) of patients treated with heparin plus a GP IIb/IIIa inhibitor. All of these bivalirudin- treated patients received concomitant acetylsalicylic acid, all but one received clopidogrel and 15 also received a GP IIb/IIIa inhibitor.</p><p><em>The ACUITY Trial (Patients with unstable angina/non-ST segment elevated myocardial infarction (UA/NSTEMI))</em></p><p>The following data are based on a clinical study of bivalirudin in 13,819 patients with ACS; 4,612 were randomised to bivalirudin alone, 4,604 were randomised to bivalirudin plus GP IIb/IIIa inhibitor and 4,603 were randomised to either unfractionated heparin or enoxaparin plus GP IIb/IIIa inhibitor. Adverse reactions were more frequent in females and in patients more than 65 years of age in both the bivalirudin and the heparin-treated comparator groups compared to male or younger patients.</p><p>Approximately 23.3% of patients receiving bivalirudin experienced at least one adverse event and 2.1% experienced an adverse reaction. Adverse event reactions for bivalirudin are listed by system organ class in Table 1.</p><ul><li>Platelets, bleeding and clotting</li></ul><p>In ACUITY, bleeding data were collected separately from adverse reactions.</p><p>Major bleeding was defined as any one of the following: intracranial, retroperitoneal, intraocular, access site haemorrhage requiring radiological or surgical intervention, &ge; 5 cm diameter haematoma at puncture site, reduction in haemoglobin concentration of &ge; 4 g/dl without an overt source of bleeding, reduction in haemoglobin concentration of &ge; 3 g/dl with an overt source of bleeding, re-operation for bleeding or use of any blood product transfusion. Minor bleeding was defined as any observed bleeding event that did not meet the criteria as major. Minor bleeding occurred very commonly (&ge; 1/10) and major bleeding occurred commonly (&ge; 1/100 and &lt; 1/10).</p><p>Major bleeding rates are shown in Table 6 for the IIT population and Table 7 for the per protocol population (patients receiving clopidogrel and acetylsalicylic acid). Both major and minor bleeds were significantly less frequent with bivalirudin alone than the heparin plus GP IIb/IIIa inhibitor and bivalirudin plus GP IIb/IIIa inhibitor groups. Similar reductions in bleeding were observed in patients who were switched to bivalirudin from heparin-based therapies (N = 2,078).</p><p>Major bleeding occurred most frequently at the sheath puncture site. Other less frequently observed bleeding sites with greater than 0.1% (uncommon) bleeding included &ldquo;other&rdquo; puncture site, retroperitoneal, gastrointestinal, ear, nose or throat.</p><p>Thrombocytopenia was reported in 10 bivalirudin-treated patients participating in the ACUITY study (0.1%). The majority of these patients received concomitant acetylsalicylic acid and clopidogrel, and 6 out of the 10 patients also received a GP IIb/IIIa inhibitor. Mortality among these patients was nil.</p><p><em>The REPLACE-2 Trial (Patients undergoing PCI)</em></p><p>The following data is based on a clinical study of bivalirudin in 6,000 patients undergoing PCI, half of whom were treated with bivalirudin (REPLACE-2). Adverse events were more frequent in females and in patients more than 65 years of age in both the bivalirudin and the heparin-treated comparator groups compared to male or younger patients.</p><p>Approximately 30% of patients receiving bivalirudin experienced at least one adverse event and 3% experienced an adverse reaction. Adverse reactions for bivalirudin are listed by system organ class in Table 1.</p><ul><li>Platelets, bleeding and clotting</li></ul><p>In REPLACE-2, bleeding data were collected separately from adverse events. Major bleeding rates for the intent-to-treat trial population are shown in Table 6.</p><p>Major bleeding was defined as the occurrence of any of the following: intracranial haemorrhage, retroperitoneal haemorrhage, blood loss leading to a transfusion of at least two units of whole blood or packed red blood cells, or bleeding resulting in a haemoglobin drop of more than 3 g/dl, or a fall in haemoglobin greater than 4 g/dl (or 12% of haematocrit) with no bleeding site identified. Minor haemorrhage was defined as any observed bleeding event that did not meet the criteria for a major haemorrhage. Minor bleeding occurred very commonly (&ge; 1/10) and major bleeding occurred commonly (&ge; 1/100 and &lt;1/10).</p><p>Both minor and major bleeds were significantly less frequent with bivalirudin than the heparin plus GP IIb/IIIa inhibitor comparator group. Major bleeding occurred most frequently at the sheath puncture site. Other less frequently observed bleeding sites with greater than 0.1% (uncommon) bleeding included &ldquo;other&rdquo; puncture site, retroperitoneal, gastrointestinal, ear, nose or throat.</p><p>In REPLACE-2 thrombocytopenia occurred in 20 bivalirudin-treated patients (0.7%). The majority of these patients received concomitant acetylsalicylic acid and clopidogrel, and 10 out of 20 patients also received a GP IIb/IIIa inhibitor. Mortality among these patients was nil.</p><p><strong>Acute cardiac events</strong></p><p><em>The HORIZONS Trial (Patients with STEMI undergoing primary PCI)</em></p><p>The following data are based on a clinical study of bivalirudin in patients with STEMI undergoing primary PCI; 1,800 patients were randomised to bivalirudin alone, 1,802 were randomised to heparin plus GP IIb/IIIa inhibitor. Serious adverse reactions were reported more frequently in the heparin plus GP IIb/IIIa group than the bivalirudin treated group.</p><p>A total of 55.1% of patients receiving bivalirudin experienced at least one adverse event and 8.7% experienced an adverse drug reaction. Adverse drug reactions for bivalirudin are listed by system organ class in Table 1. The incidence of stent thrombosis within the first 24 hours was 1.5% in patients receiving bivalirudin versus 0.3% in patients receiving UFH plus GP IIb/IIIa inhibitor (p=0.0002).</p><p>Two deaths occurred after acute stent thrombosis, 1 in each arm of the study. The incidence of stent thrombosis between 24 hours and 30 days was 1. 2% in patients receiving bivalirudin versus 1.9% in patients receiving UFH plus GP IIb/IIIa inhibitor (p=0.1553). A total of 17 deaths occurred after subacute stent thrombosis, 3 in the bivalirudin arm and 14 in the UFH plus GP IIb/IIIa arm. There was no statistically significant difference in the rates of stent thrombosis between treatment arms at 30 days (p=0.3257) and 1 year (p=0.7754).</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cases of overdose of up to 10 times the recommended dose have been reported in clinical trials. Single bolus doses of bivalirudin up to 7.5 mg/kg have also been reported. Bleeding has been observed in some reports of overdose.</p><p>In cases of overdose, treatment with bivalirudin should be immediately discontinued and the patient monitored closely for signs of bleeding.</p><p>In the event of major bleeding, treatment with bivalirudin should be immediately discontinued. There is no known antidote to bivalirudin, however, bivalirudin is haemo-dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antithrombotic agents, Direct thrombin inhibitors, ATC code: B01AE06.</p><p><strong>Mechanism of action</strong></p><p>Bilvardi contains bivalirudin, a direct and specific thrombin inhibitor that binds both to the catalytic site and the anion-binding exosite of fluid-phase and clot-bound thrombin.</p><p>Thrombin plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross- linked framework that stabilises the thrombus. Thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release. Bivalirudin inhibits each of these thrombin effects.</p><p>The binding of bivalirudin to thrombin, and therefore its activity, is reversible as thrombin slowly cleaves the bivalirudin, Arg3-Pro4, bond, resulting in recovery of thrombin active site function. Thus, bivalirudin initially acts as a complete non-competitive inhibitor of thrombin, but transitions over time to become a competitive inhibitor enabling initially inhibited thrombin molecules to interact with other clotting substrates and to coagulation if required.</p><p>In vitro studies have indicated that bivalirudin inhibits both soluble (free) and clot-bound thrombin. Bivalirudin remains active and is not neutralised by products of the platelet release reaction.</p><p>In vitro studies have also shown that bivalirudin prolongs the activated partial thromboplastin time (aPTT) thrombin time (TT) and pro-thrombin time (PT) of normal human plasma in a concentration- dependent manner and that bivalirudin does not induce a platelet aggregation response against sera from patients with a history of Heparin-Induced Thrombocytopenia/Thrombosis Syndrome (HIT/HITTS).</p><p>In healthy volunteers and patients, bivalirudin exhibits dose- and concentration-dependent anticoagulant activity as evidenced as prolongation of the ACT, aPTT, PT, INR and TT. Intravenous administration of bivalirudin produces measurable anticoagulation within minutes.</p><p><strong>Pharmacodynamic effects</strong></p><p>The pharmacodynamic effects of bivalirudin may be assessed using measures of anticoagulation including the ACT. The ACT value is positively correlated with the dose and plasma concentration of bivalirudin administered. Data from 366 patients indicates that the ACT is unaffected by concomitant treatment with a GP IIb/IIIa inhibitor.</p><p><strong>Clinical efficacy and safety</strong></p><p>In clinical studies bivalirudin has been shown to provide adequate anticoagulation during PCI procedures.</p><p><em>The HORIZONS Trial (Patients with STEMI undergoing primary PCI)</em></p><p>The HORIZONS trial was a prospective, dual arm, single blind, randomised, multicentre trial to establish the safety and efficacy of bivalirudin in patients with STEMI undergoing a primary PCI strategy with stent implantation with either a slow release paclitaxel-eluding stent (TAXUS&trade;) or an otherwise identical uncoated bare metal stent (Express2&trade;). A total of 3,602 patients were randomised to receive either bivalirudin (1,800 patients) or unfractionated heparin plus a GP IIb/IIIa inhibitor (1,802 patients). All patients received acetylsalicylic acid and clopidogrel with twice as many patients (approximately 64%) receiving a 600mg loading dose of clopidogrel than a 300mg loading dose of clopidogrel. Approximately 66% of patients were pre-treated with unfractionated heparin.</p><p>The dose of bivalirudin used in HORIZONS was the same as that used in the REPLACE-2 study (0.75 mg/kg bolus followed by a 1.75 mg/kg body weight/hour infusion). A total of 92.9% of patients treated underwent primary PCI as their primary management strategy.</p><p>The analysis and results for the HORIZONS trial at 30 days for the overall (ITT) population is shown in Table 2. Results at 1 year were consistent with results at 30 days.</p><p>Bleeding definitions and outcomes from the HORIZONS trial are shown in Table 6.</p><p><strong>Table 2. HORIZONS 30-day study results (intent-to-treat population) </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Bivalirudin (%)</strong></p></td><td style="vertical-align:top"><p><strong>Unfractionated heparin + GP IIb/IIIa inhibitor (%)</strong></p></td><td style="vertical-align:top"><p><strong>Relative Risk [95 % CI]</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>p- value*</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>N = 1,800</strong></p></td><td style="vertical-align:top"><p><strong>N = 1,802</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>30-day composite</strong></p></td></tr><tr><td style="vertical-align:top"><p>MACE<sup>1</sup></p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>0.98</p><p>[0.75, 1.29]</p></td><td style="vertical-align:top"><p>0.8901</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Major bleeding<sup>2</sup></p></td><td style="vertical-align:top"><p>5.1</p></td><td style="vertical-align:top"><p>8.8</p></td><td style="vertical-align:top"><p>0.58</p><p>[0.45, 0.74]</p></td><td style="vertical-align:top"><p>&lt; 0.0001</p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Ischaemic Components</strong></p></td></tr><tr><td style="vertical-align:top"><p>All cause death</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>3.1</p></td><td style="vertical-align:top"><p>0.66</p><p>[0.44, 1.0]</p></td><td style="vertical-align:top"><p>0.465</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Reinfarction</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>1.06</p><p>[0.66, 1.72]</p></td><td style="vertical-align:top"><p>0.8003</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ischaemic target vessel revascularisation</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>1.29</p><p>[0.93, 1.99]</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>0.2561</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Stroke</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>1.17</p><p>[0.54, 2.52]</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>0.6917</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p>*Superiority p-value</p><p><sup>1</sup>Major Adverse Cardiac/Ischaemic Events (MACE) was defined as the occurrence of any of the following; death, reinfarction, stroke or ischaemic target vessel revascularisation.</p><p><sup>2</sup>Major bleeding was defined using the ACUITY bleeding scale.</p><p><em>ACUITY Trial (Patients with unstable angina/non-ST segment elevated myocardial infarction (UA/NSTEMI)</em></p><p>The ACUITY trial was a prospective, randomised open-label, trial of bivalirudin with or without GP IIb/IIIa inhibitor (Arms B and C respectively) versus unfractionated heparin or enoxaparin with GP IIb/IIIa inhibitor (Arm A) in 13,819 high risk ACS patients.</p><p>In Arms B and C of the ACUITY trial, the recommended dose of bivalirudin was an initial post- randomisation intravenous bolus of 0.1 mg/kg followed by a continuous intravenous infusion of 0.25 mg/kg/h during angiography or as clinically warranted.</p><p>For patients undergoing PCI, an additional intravenous bolus of 0.5 mg/kg bivalirudin was administered and the rate of intravenous infusion increased to 1.75 mg/kg/h.</p><p>In Arm A of the ACUITY trial, UFH or enoxaparin was administered in accordance with the relevant guidelines for the management of ACS in patients with UA and NSTEMI. Patients in Arms A and B were also randomised to receive a GP IIb/IIIa inhibitor either upfront at the time of randomization (prior to angiography) or at the time of PCI. A total of 356 (7.7%) of patients randomised to Arm C also received a GP IIb/IIIa inhibitor.</p><p>High risk patient characteristics of the ACUITY population that mandated angiography within 72 hours were balanced across the three treatment arms. Approximately 77% of patients had recurrent ischaemia, approximately 70% had dynamic ECG changes or elevated cardiac biomarkers, approximately 28% had diabetes and approximately 99% of patients underwent angiography within 72 hours.</p><p>Following angiographic assessment, patients were triaged to either medical management (33%), PCI (56%) or CABG (11%). Additional anti-platelet therapy utilised in the study included acetylsalicylic acid and clopidogrel.</p><p>The primary analysis and results for ACUITY at 30-days and 1 year for the overall (ITT) population and for the patients that received acetylsalicylic acid and clopidogrel as per protocol (pre-angiography or pre- PCI) are shown in Tables 3 and 4.</p><p><strong>Table 3. ACUITY trial; 30-day and 1-year risk differences for the composite ischaemic endpoint and its components for the overall population (ITT)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Overall population (ITT)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Arm A</strong></p><p><strong>UFH/enox+GP IIb/IIIa inhibitor</strong></p><p><strong>(N=4,603)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Arm B</strong></p><p><strong>bival+GP</strong></p><p><strong>IIb/IIIa</strong></p><p><strong>inhibitor</strong></p><p><strong>(N=4,604)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>B &ndash; A Risk diff.</strong></p><p><strong>(95% CI)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Arm C bival alone</strong></p><p><strong>(N=4,612)</strong></p><p><strong>%</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>C &ndash; A Risk diff.</strong></p><p><strong>(95% CI)</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>30-day</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Composite ischaemia</strong></p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>7.7</p></td><td style="vertical-align:top"><p>0.48</p><p>(-0.60, 1.55)</p></td><td style="vertical-align:top"><p>7.8</p></td><td style="vertical-align:top"><p>0.55</p><p>(-0.53, 1.63)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Death</strong></p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>1.5</p></td><td style="vertical-align:top"><p>0.17</p><p>(-0.31, 0.66)</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>0.26</p><p>(-0.23, 0.75)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MI</strong></p></td><td style="vertical-align:top"><p>4.9</p></td><td style="vertical-align:top"><p>5.0</p></td><td style="vertical-align:top"><p>0.04</p><p>(-0.84, 0.93)</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>0.45</p><p>(-0.46, 1.35)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unplanned revasc.</strong></p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>0.39</p><p>(-0.24, 1.03)</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>0.10</p><p>(-0.51, 0.72)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>1-year</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Composite ischaemia</strong></p></td><td style="vertical-align:top"><p>15.3</p></td><td style="vertical-align:top"><p>15.9</p></td><td style="vertical-align:top"><p>0.65</p><p>(-0.83, 2.13)</p></td><td style="vertical-align:top"><p>16.0</p></td><td style="vertical-align:top"><p>0.71</p><p>(-0.77, 2.19)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Death</strong></p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>0.04</p><p>(-0.83, 0.74)</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>-0.18</p><p>(-0.96, 0.60)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MI</strong></p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>0.19</p><p>(-0.84, 1.23)</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>0.83</p><p>(-0.22, 1.89)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unplanned revasc.</strong></p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>8.8</p></td><td style="vertical-align:top"><p>0.78</p><p>(-0.36, 1.92)</p></td><td style="vertical-align:top"><p>8.4</p></td><td style="vertical-align:top"><p>0.37</p><p>(-0.75, 1.50)</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>Table 4. ACUITY trial; 30-day and 1-year risk differences for the composite ischaemic endpoint and its components for patients that received acetylsalicylic acid and clopidogrel as per protocol*</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Overall population (ITT)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Arm A</strong></p><p><strong>UFH/enox+GP IIb/IIIa inhibitor</strong></p><p><strong>(N=2,842)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Arm B</strong></p><p><strong>bival+GP IIb/IIIa inhibitor</strong></p><p><strong>(N=2,924)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>B &ndash; A Risk diff.</strong></p><p><strong>(95% CI)</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Arm C bival alone</strong></p><p><strong>(N=2,911)</strong></p><p><strong>%</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>C &ndash; A Risk diff.</strong></p><p><strong>(95% CI)</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>30-day</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Composite ischaemia</strong></p></td><td style="vertical-align:top"><p>7.4</p></td><td style="vertical-align:top"><p>7.4</p></td><td style="vertical-align:top"><p>0.03</p><p>(-1.32, 1.38)</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>-0.35</p><p>(-1.68, 0.99)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Death</strong></p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>-0.00</p><p>(-0.60, 0.60)</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>-0.14</p><p>(-0.72, 0.45)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MI</strong></p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>4.9</p></td><td style="vertical-align:top"><p>0.04</p><p>(-1.07,1.14)</p></td><td style="vertical-align:top"><p>4.7</p></td><td style="vertical-align:top"><p>-0.08</p><p>(-1.18, 1.02)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unplanned revasc.</strong></p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>0.23</p><p>(-0.61, 1.08)</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>-0.41</p><p>(-1.20, 0.39)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>1-year</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Composite ischaemia</strong></p></td><td style="vertical-align:top"><p>16.1</p></td><td style="vertical-align:top"><p>16.8</p></td><td style="vertical-align:top"><p>0.68</p><p>(-1.24, 2.59)</p></td><td style="vertical-align:top"><p>15.8</p></td><td style="vertical-align:top"><p>-0.35</p><p>(-2.24, 1.54)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Death</strong></p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>0.20</p><p>(-0.78, 1.19)</p></td><td style="vertical-align:top"><p>3.3</p></td><td style="vertical-align:top"><p>-0.36</p><p>(-1.31, 0.59)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MI</strong></p></td><td style="vertical-align:top"><p>6.7</p></td><td style="vertical-align:top"><p>7.3</p></td><td style="vertical-align:top"><p>0.60</p><p>(-0.71, 1.91)</p></td><td style="vertical-align:top"><p>6.8</p></td><td style="vertical-align:top"><p>0.19</p><p>(-1.11, 1.48)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Unplanned revasc.</strong></p></td><td style="vertical-align:top"><p>9.4</p></td><td style="vertical-align:top"><p>10.0</p></td><td style="vertical-align:top"><p>0.59</p><p>(-0.94, 2.12)</p></td><td style="vertical-align:top"><p>8.9</p></td><td style="vertical-align:top"><p>-0.53</p><p>(-2.02, 0.96)</p></td></tr></tbody></table><p>*clopidogrel pre-angiography or pre-PCI</p><p>The incidence of both ACUITY-scale and TIMI-scale bleeding events up to day 30 for the intent-to- treat population is presented in Table 6. The incidence of both ACUITY-scale and TIMI-scale bleeding events to day 30 for the per protocol population are presented in Table 7. The advantage of bivalirudin over UFH/enoxaparin plus GP IIb/IIIa inhibitor in terms of bleeding events was only observed in the bivalirudin monotherapy arm.</p><p><em>The REPLACE-2 Trial (Patients undergoing PCI)</em></p><p>The 30-day results based on quadruple and triple endpoints from a randomized, double-blind trial of over 6,000 patients undergoing PCI (REPLACE-2) are shown in Table 5. Bleeding definitions and outcomes from the REPLACE-2 trial are shown in Table 6.</p><p><strong>Table 5. REPLACE-2 study results: 30-day endpoints (intend-to-treat and perprotocol</strong></p><p><strong>populations)</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Endpoint</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Intent-to-treat</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Per-protocol</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Bivalirudin</strong></p><p><strong>(N=2,994)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Heparin + GP IIb/IIIa inhibitor</strong></p><p><strong>(N=3,008)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Bivalirudin</strong></p><p><strong>(N = 2,902)</strong></p><p><strong>%</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Heparin + GP IIb/IIIa inhibitor</strong></p><p><strong>(N=2,902)</strong></p><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p>Quadruple endpoint</p></td><td style="vertical-align:top"><p>9.2</p></td><td style="vertical-align:top"><p>10.0</p></td><td style="vertical-align:top"><p>9.2</p></td><td style="vertical-align:top"><p>10.0</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Triple endpoint*</p></td><td style="vertical-align:top"><p>7.6</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>9.2</p></td><td style="vertical-align:top"><p>7.1</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Components:</p></td></tr><tr><td style="vertical-align:top"><p>Death</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0.4</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Myocardial Infarction</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>6.2</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>6.4</p></td></tr><tr><td style="vertical-align:top"><p>Major bleeding ** (based on non-TIMI criteria, see section 4.8)</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>4.1</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>4.0</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Urgent revascularisation</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.3</p><p>&nbsp;</p></td></tr></tbody></table><p>*excludes major bleeding component</p><p>** p &lt;0.001</p><p><strong>Table 6. Major bleeding rates in clinical trials of bivalirudin 30-day endpoints for intent-to-treat populations </strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Bivalirudin (%)</strong></p></td><td style="vertical-align:top"><p><strong>Bival+GP II/IIIa inhibitor</strong></p><p><strong>(%)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>UFH/Enox1 + GP IIb/IIIa inhibitor</strong></p><p><strong>(%)</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>REPLACE-2</p></td><td style="vertical-align:top"><p>ACUITY</p></td><td style="vertical-align:top"><p>HORIZONS</p></td><td style="vertical-align:top"><p>ACUITY</p></td><td style="vertical-align:top"><p>REPLACE-2</p></td><td style="vertical-align:top"><p>ACUITY</p></td><td style="vertical-align:top"><p>HORIZONS</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>N = 2,994</p></td><td style="vertical-align:top"><p>N=4,612</p></td><td style="vertical-align:top"><p>N = 1,800</p></td><td style="vertical-align:top"><p>N= 4,604</p></td><td style="vertical-align:top"><p>N = 3,008</p></td><td style="vertical-align:top"><p>N=4,603</p></td><td style="vertical-align:top"><p>N = 1,802</p></td></tr><tr><td style="vertical-align:top"><p><strong>Protocol defined major bleeding</strong></p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>5.1</p></td><td style="vertical-align:top"><p>5.3</p></td><td style="vertical-align:top"><p>4.1</p></td><td style="vertical-align:top"><p>5.7</p></td><td style="vertical-align:top"><p>8.8</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>TIMI Major (non CABG) Bleeding</strong></p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>3.2</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><sup>1</sup>Enoxaparin was used as comparator in ACUITY only.</p><p><strong>Table 7. ACUITY trial; bleeding events up to day 30 for the population of patients who received acetylsalicylic acid and clopidogrel as per protocol*</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>UFH/enox + GP IIb/IIIa inhibitor</strong></p><p><strong>(N= 2,842) %</strong></p></td><td style="vertical-align:top"><p><strong>Bival + GP IIb/IIIa inhibitor</strong></p><p><strong>(N=2,924) %</strong></p></td><td style="vertical-align:top"><p><strong>Bival alone</strong></p><p><strong>(N=2,911) %</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>ACUITY scale major bleeding</p></td><td style="vertical-align:top"><p>5.9</p></td><td style="vertical-align:top"><p>5.4</p></td><td style="vertical-align:top"><p>3.1</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>TIMI scale major bleeding</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>0.8</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p>*clopidogrel pre-angiography or pre-PCI</p><p><em>Bleeding Definitions</em></p><p>REPLACE-2 major bleeding was defined as the occurrence of any of the following: intracranial haemorrhage, retroperitoneal haemorrhage, blood loss leading to a transfusion of at least two units of whole blood or packed red blood cells, or bleeding resulting in a haemoglobin drop of more than 3 g/dl, or a fall in haemoglobin greater than 4 g/dl (or 12% of haematocrit) with no bleeding site identified. ACUITY major bleeding was defined as any one of the following: intracranial, retroperitoneal, intraocular, access site haemorrhage requiring radiological or surgical intervention, &ge; 5 cm diameter haematoma at puncture site, reduction in haemoglobin concentration of &ge; 4 g/dl without an overt source of bleeding, reduction in haemoglobin concentration of &ge; 3 g/dl with an overt source of bleeding, re-operation for bleeding, use of any blood product transfusion. Major bleeding in the HORIZONS study was also defined using the ACUITY scale. TIMI major bleeding was defined as intracranial bleeding or a decrease in haemoglobin concentration &ge; 5 g/dl.</p><p><em>Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopeniathrombosis</em></p><p><em>syndrome (HIT/HITTS)</em></p><p>Clinical trials in a small number of patients have provided limited information about the use of bivalirudin in patients with HIT/HITTS.</p><p><strong>Paediatric population</strong></p><p>In clinical study TMC-BIV-07-01, the pharmacodynamic response as measured by ACT was consistent with adult studies. The ACT increased in all patients, from neonates to older children as well as adults, with increasing bivalirudin concentrations. The ACT vs concentration data suggest a trend for a lower concentration response curve for adults as compared to older children (6 years to &lt; 16 years) and younger children (2 years to &lt; 6 years), and for older children compared to infants (31 days to &lt; 24 months) and neonates (birth to 30 days). Pharmacodynamic models indicated that this effect is due to a higher baseline ACT in neonates and infants than in older children. However, the maximal ACT values for all groups (adults and all paediatric groups) converge at a similar level near an ACT of 400 seconds. The clinical utility of ACT in neonates and children should be considered with caution considering their developmental haematological state.</p><p>Thrombotic (9/110, 8.2%) and major bleeding events (2/110, 1.8%) were observed in the study. Other frequently reported adverse events were decreased pedal pulse, catheter site haemorrhage, abnormal pulse, and nausea (8.2%, 7.3%, 6.4% and 5.5%, respectively). Five patients had a post-baseline nadir platelet count of &lt; 150,000 cells/mm3, representing a &ge; 50% decrease in platelets from baseline. All 5 events were associated with additional cardiac procedures employing heparin anticoagulation (n=3) or with infections (n=2). A population pharmacokinetic/pharmacodynamic analysis, and an Exposure and Adverse Event Assessment Model based on the data from this study determined that in paediatric patients, use of the adult dosing with plasma levels similar to that achieved in adults was associated with lower levels of thrombotic events with no impact on bleeding events (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of bivalirudin have been evaluated and found to be linear in patients undergoing Percutaneous Coronary Intervention and in patients with ACS.</p><p><strong>Absorption</strong></p><p>The bioavailability of bivalirudin for intravenous use is complete and immediate. The mean steady- state concentration of bivalirudin following a constant intravenous infusion of 2.5 mg/kg/h is 12.4 &mu;g/ml.</p><p><strong>Distribution</strong></p><p>Bivalirudin is rapidly distributed between plasma and extracellular fluid. The steady-state volume of distribution is 0.1 l/kg. Bivalirudin does not bind to plasma proteins (other than thrombin) or to red blood cells.</p><p><strong>Biotransformation</strong></p><p>As a peptide, bivalirudin is expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acid in the body pool. Bivalirudin is metabolized by proteases, including thrombin. The primary metabolite resulting from the cleavage of Arg3-Pro4 bond of the N- terminal sequence by thrombin is not active because of the loss of affinity to the catalytic active site of thrombin. About 20% of bivalirudin is excreted unchanged in the urine.</p><p><strong>Elimination</strong></p><p>The concentration-time profile following intravenous administration is well described by a two- compartment model. Elimination follows a first order process with a terminal half-life of 25 &plusmn; 12 minutes in patients with normal renal function. The corresponding clearance is about 3.4 &plusmn; 0.5 ml/min/kg.</p><p><strong>Hepatic Insufficiency</strong></p><p>The pharmacokinetics of bivalirudin have not been studied in patients with hepatic impairment but are not expected to be altered because bivalirudin is not metabolized by liver enzymes such as cytochrome P-450 isozymes.</p><p><strong>Renal Insufficiency</strong></p><p>The systemic clearance of bivalirudin decreases with glomerular filtration rate (GFR). The clearance of bivalirudin is similar in patients with normal renal function and those with mild renal impairment. Clearance is reduced by approximately 20% in patients with moderate or severe renal impairment, and 80% in dialysis-dependent patients (Table 8).</p><p><strong>Table 8. Pharmacokinetic parameters for bivalirudin in patients with normal and impaired renal function</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Renal function (GFR)</strong></p></td><td style="vertical-align:top"><p><strong>Clearance</strong></p><p><strong>(ml/min/kg)</strong></p></td><td style="vertical-align:top"><p><strong>Half-life (minutes)</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Normal renal function (&ge; 90ml/min)</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>25</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Mild renal impairment (60-89 ml/min)</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>22</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Moderate renal impairment (30-59 ml/min)</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>34</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Severe renal impairment (10-29 ml/min)</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>57</p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dialysis dependent patients (off-dialysis)</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>3.5 hours</p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>Elderly</strong></p><p>Pharmacokinetics have been evaluated in elderly patients as part of a renal pharmacokinetic study. Dose adjustments for this age group should be on the basis of renal function, see section 4.2.</p><p><strong>Gender</strong></p><p>There are no gender effects in the pharmacokinetics of bivalirudin.</p><p><strong>Paediatric population</strong></p><p>In a clinical trial of 110 paediatric patients (neonates to &lt; 16 years of age) undergoing percutaneous intravascular procedures, the safety, pharmacokinetic and pharmacodynamic profile of bivalirudin was evaluated [TMC-BIV-07-01]. The approved adult weight-based intravenous bolus dose of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/hour was studied and pharmacokinetic/pharmacodynamic analysis found a response similar to that of adults, although weight-normalized clearance (ml/min/kg) of bivalirudin was higher in neonates than in older children and decreased with increasing age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety, pharmacology, repeated dose toxicity, genotoxicity, or toxicity to reproduction.</p><p>Toxicity in animals upon repeated or continuous exposure (1 day to 4 weeks at exposure levels of up to 10 times the clinical steady state plasma concentration) was limited to exaggerated pharmacological effects. Comparison of the single and repeated dose studies revealed that toxicity was related primarily to duration of exposure. All the undesirable effects, primary and secondary, resulting from excessive pharmacological activity were reversible. Undesirable effects that resulted from prolonged physiological stress in response to a non-homeostatic state of coagulation were not seen after short exposure comparable to that in clinical use, even at much higher doses.</p><p>Bivalirudin is intended for short-term administration and therefore no data on the long-term carcinogenic potential of bivalirudin are available. However, bivalirudin was not mutagenic or clastogenic in standard assays for such effects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Mannitol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Sodium hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following medicinal products should not be administered in the same intravenous line as bivalirudin since they result in haze formation, micro-particulate formation or gross precipitation; alteplase, amiodarone HCl, amphotericin B, chlorpromazine hydrochloride (HCl), diazepam, prochlorperazine edisylate, reteplase, streptokinase and vancomycin HCl.</p><p>The following six medicinal products show dose-concentration incompatibilities with bivalirudin. Table 9 summarises compatible and incompatible concentrations of these compounds. The medicinal products incompatible with bivalirudin at higher concentrations are: dobutamine hydrochloride, famotidine, haloperidol lactate, labetalol hydrochloride, lorazepam and promethazine HCl.</p><p><strong>Table 9. Medicinal products with dose concentration incompatibilities to bivalirudin</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal products with dose concentration incompatibilities</strong></p></td><td style="vertical-align:top"><p><strong>Compatible concentrations</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Incompatible concentrations</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dobutamine HCl</p></td><td style="vertical-align:top"><p>4 mg/ml</p></td><td style="vertical-align:top"><p>12.5 mg/ml</p></td></tr><tr><td style="vertical-align:top"><p>Famotidine</p></td><td style="vertical-align:top"><p>2 mg/ml</p></td><td style="vertical-align:top"><p>10 mg/ml</p></td></tr><tr><td style="vertical-align:top"><p>Haloperidol lactate</p></td><td style="vertical-align:top"><p>0.2 mg/ml</p></td><td style="vertical-align:top"><p>5 mg/ml</p></td></tr><tr><td style="vertical-align:top"><p>Labetalol HCl</p></td><td style="vertical-align:top"><p>2 mg/ml</p></td><td style="vertical-align:top"><p>5 mg/ml</p></td></tr><tr><td style="vertical-align:top"><p>Lorazepam</p></td><td style="vertical-align:top"><p>0.5 mg/ml</p></td><td style="vertical-align:top"><p>2 mg/ml</p></td></tr><tr><td style="vertical-align:top"><p>Promethazine HCl</p></td><td style="vertical-align:top"><p>2 mg/ml</p></td><td style="vertical-align:top"><p>25 mg/ml</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
Reconstituted solution: Chemical and physical in-use stability has been demonstrated for 24 hours at 2-8°C.
Diluted solution: Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2- 8°C unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original package.</p><p><em>Reconstituted solution: </em>Store in a refrigerator (2-8&deg;C) for 24 hours. Avoid freezing.</p><p><em>Diluted solution: </em>The diluted solution is stored at 25&deg;C for 24 hours. Avoid freezing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 ml single-use type I clear glass vials closed with a bromobutyl rubber stoppers and sealed with an aluminum-plastic overseal.</p><p>Pack size: 10 Vials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Instructions for preparation</strong></p><p>Aseptic procedures should be used for the preparation and administration of Bilvardi.</p><p>Add 5 ml sterile water for injections to one vial of Bilvardi and swirl gently until completely dissolved and the solution is clear. Reconstitution should take approximately 1 minute to complete.</p><p>Withdraw 5 ml from the vial, and further dilute in a total volume of 50 ml of glucose 5% solution for injection, or sodium chloride 9 mg/ml (0.9%) solution for injection to give a final bivalirudin concentration of 5 mg/ml.</p><p>The reconstituted/diluted solution should be inspected visually for particulate matter and discolouration. Solutions containing particulate matter should not be used. Discoloured solutions should not be used.</p><p>The reconstituted/diluted solution will be a clear to slightly opalescent, colourless solution.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements<strong>.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17 January 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>